s_id
stringlengths 2
9
| r_id
stringlengths 2
6
| e_id
stringlengths 2
10
| s_label
stringlengths 1
250
| r_label
stringlengths 2
66
| e_label
stringlengths 1
265
|
|---|---|---|---|---|---|
Q37127097
|
P2860
|
Q77229046
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor
|
Q37127097
|
P2860
|
Q84578275
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Allopurinol: novel indications in cardiovascular disease
|
Q37127097
|
P2860
|
Q84494875
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions
|
Q37127097
|
P2860
|
Q68255434
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide
|
Q37127097
|
P2860
|
Q84384051
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Allopurinol-induced DRESS syndrome
|
Q37127097
|
P2860
|
Q83555387
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Febuxostat hypersensitivity
|
Q37127097
|
P2860
|
Q73123213
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes
|
Q37127097
|
P2860
|
Q87289805
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Antihyperuricemic effects of thiadiazolopyrimidin-5-one analogues in oxonate treated rats
|
Q37127097
|
P2860
|
Q89181859
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study
|
Q37127097
|
P2860
|
Q60711768
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-κB
|
Q37127097
|
P2860
|
Q87331713
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Design, synthesis and molecular modeling of aloe-emodin derivatives as potent xanthine oxidase inhibitors
|
Q37127097
|
P2860
|
Q85229485
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
A new cycloartane-type triterpenoid saponin xanthine oxidase inhibitor from Homonoia riparia Lour
|
Q37127097
|
P2860
|
Q60637933
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Immunohistochemical localization of xanthine oxidase in human cardiac and skeletal muscle
|
Q37127097
|
P2860
|
Q73403772
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Biotransformation of protocatechuic aldehyde and caffeic acid to vanillin and capsaicin in freely suspended and immobilized cell cultures of Capsicum frutescens
|
Q37127097
|
P2860
|
Q68791382
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Hypouricemia and hyperuricosuria in Laennec cirrhosis
|
Q37127097
|
P2860
|
Q71995282
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Hypochlorite induces lipid peroxidation in blood lipoproteins and phospholipid liposomes
|
Q37127097
|
P2860
|
Q85312726
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Synthesis and xanthine oxidase inhibitory activity of 5,6-dihydropyrazolo/pyrazolo[1,5-c]quinazoline derivatives
|
Q37127097
|
P2860
|
Q85289299
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Synthesis and Biological Evaluation of Novel Aryl-2H-pyrazole Derivatives as Potent Non-purine Xanthine Oxidase Inhibitors
|
Q37127097
|
P2860
|
Q70144052
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression
|
Q37127097
|
P2860
|
Q84617958
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008
|
Q37127097
|
P2860
|
Q73873383
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
XDH gene mutation is the underlying cause of classical xanthinuria: a second report
|
Q37127097
|
P2860
|
Q87418169
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
cites work
|
Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease
|
Q37127097
|
P921
|
Q49970
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
main subject
|
hyperuricemia
|
Q37127097
|
P921
|
Q8047
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
main subject
|
enzyme
|
Q37127097
|
P921
|
Q3271540
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
main subject
|
mechanism of action
|
Q37127097
|
P921
|
Q427492
|
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
|
main subject
|
enzyme inhibitor
|
Q37127111
|
P31
|
Q101352
|
Deats
|
instance of
|
family name
|
Q37127111
|
P282
|
Q8229
|
Deats
|
writing system
|
Latin script
|
Q37127111
|
P5323
|
Q92953148
|
Deats
|
attested in
|
2010 United States Census surname index
|
Q37127115
|
P31
|
Q101352
|
Brindley
|
instance of
|
family name
|
Q37127115
|
P1889
|
Q917359
|
Brindley
|
different from
|
Brindley
|
Q37127115
|
P407
|
Q1860
|
Brindley
|
language of work or name
|
English
|
Q37127115
|
P282
|
Q8229
|
Brindley
|
writing system
|
Latin script
|
Q37127115
|
P5323
|
Q92953148
|
Brindley
|
attested in
|
2010 United States Census surname index
|
Q37127119
|
P31
|
Q13442814
|
Monocular Deprivation in Mice
|
instance of
|
scholarly article
|
Q37127119
|
P1433
|
Q27725732
|
Monocular Deprivation in Mice
|
published in
|
Bio-protocol
|
Q37127119
|
P2860
|
Q37032417
|
Monocular Deprivation in Mice
|
cites work
|
Downregulation of cortical inhibition mediates ocular dominance plasticity during the critical period
|
Q37127119
|
P2860
|
Q51282197
|
Monocular Deprivation in Mice
|
cites work
|
RECEPTIVE FIELDS OF CELLS IN STRIATE CORTEX OF VERY YOUNG, VISUALLY INEXPERIENCED KITTENS
|
Q37127119
|
P50
|
Q58331188
|
Monocular Deprivation in Mice
|
author
|
Ya-tang Li
|
Q37127120
|
P31
|
Q101352
|
Chorey
|
instance of
|
family name
|
Q37127120
|
P282
|
Q8229
|
Chorey
|
writing system
|
Latin script
|
Q37127120
|
P5323
|
Q92953148
|
Chorey
|
attested in
|
2010 United States Census surname index
|
Q37127135
|
P31
|
Q13442814
|
Antiatherogenic functionality of high density lipoprotein: how much versus how good
|
instance of
|
scholarly article
|
Q37127135
|
P31
|
Q7318358
|
Antiatherogenic functionality of high density lipoprotein: how much versus how good
|
instance of
|
review article
|
Q37127135
|
P1433
|
Q26842628
|
Antiatherogenic functionality of high density lipoprotein: how much versus how good
|
published in
|
Journal of Atherosclerosis and Thrombosis
|
Q37127135
|
P921
|
Q28350
|
Antiatherogenic functionality of high density lipoprotein: how much versus how good
|
main subject
|
lipoprotein
|
Q37127135
|
P50
|
Q91944002
|
Antiatherogenic functionality of high density lipoprotein: how much versus how good
|
author
|
Alan T. Remaley
|
Q37127140
|
P31
|
Q13442814
|
Mechanism of pi-induced vascular calcification
|
instance of
|
scholarly article
|
Q37127140
|
P31
|
Q7318358
|
Mechanism of pi-induced vascular calcification
|
instance of
|
review article
|
Q37127140
|
P1433
|
Q26842628
|
Mechanism of pi-induced vascular calcification
|
published in
|
Journal of Atherosclerosis and Thrombosis
|
Q37127156
|
P31
|
Q13442814
|
Autonomous control of oxygenation
|
instance of
|
scholarly article
|
Q37127156
|
P31
|
Q7318358
|
Autonomous control of oxygenation
|
instance of
|
review article
|
Q37127156
|
P1433
|
Q15766545
|
Autonomous control of oxygenation
|
published in
|
Journal of Trauma
|
Q37127156
|
P407
|
Q1860
|
Autonomous control of oxygenation
|
language of work or name
|
English
|
Q37127158
|
P31
|
Q13442814
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
instance of
|
scholarly article
|
Q37127158
|
P1433
|
Q15758529
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
published in
|
British Journal of Radiology
|
Q37127158
|
P2860
|
Q33844873
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiob
|
Q37127158
|
P2860
|
Q35749557
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Loss of biological effect in prolonged fraction delivery
|
Q37127158
|
P2860
|
Q33989975
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix
|
Q37127158
|
P2860
|
Q36838126
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy.
|
Q37127158
|
P2860
|
Q42618261
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer
|
Q37127158
|
P2860
|
Q52391669
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Derivation and application of equations describing the effects of fractionated protracted irradiation, based on multiple and incomplete repair processes. Part I. Derivation of equations.
|
Q37127158
|
P2860
|
Q48458975
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Clinical outcome for chemoradiotherapy in carcinoma of the cervix.
|
Q37127158
|
P2860
|
Q51755084
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Effects of very low dose-rate (90)Sr/(90)Y exposure on the acute moist desquamation response of pig skin.
|
Q37127158
|
P2860
|
Q51935118
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Radiobiological modelling of dose-gradient effects in low dose rate, high dose rate and pulsed brachytherapy.
|
Q37127158
|
P2860
|
Q52372933
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Two components of repair in irradiated kidney colony forming cells.
|
Q37127158
|
P2860
|
Q52340800
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Monte Carlo aided dosimetry of the microselectron pulsed and high dose-rate 192Ir sources.
|
Q37127158
|
P2860
|
Q58376374
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Compensation for changes in dose-rate in radical low-dose-rate brachytherapy: a radiobiological analysis of a randomised clinical trial
|
Q37127158
|
P2860
|
Q59138882
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Point: Why choose pulsed-dose-rate brachytherapy for treating gynecologic cancers?
|
Q37127158
|
P2860
|
Q80944705
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study
|
Q37127158
|
P2860
|
Q73865645
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Is pulsed dose rate more damaging to spinal cord of rats than continuous low dose rate?
|
Q37127158
|
P2860
|
Q80813867
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Retrospective dosimetric comparison of low-dose-rate and pulsed-dose-rate intracavitary brachytherapy using a tandem and mini-ovoids
|
Q37127158
|
P2860
|
Q79611036
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Brachytherapy for carcinoma of the cervix: a Canadian survey of practice patterns in a changing era
|
Q37127158
|
P2860
|
Q62269576
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
The effect of alternative biological modelling parameters (α/β and half time of repair T1/2) on reported EQD2 values in the treatment of advanced cervical cancer
|
Q37127158
|
P2860
|
Q85633782
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
The implementation of the Gynaecological Groupe Européen de Curiethérapie - European Society for Therapeutic Radiology and Oncology radiobiology considerations in the conversion of low dose rate to pulsed dose rate treatment schedules for gynaecolog
|
Q37127158
|
P2860
|
Q73930726
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Radiation tolerance of rat spinal cord to pulsed dose rate (PDR-) brachytherapy: the impact of differences in temporal dose distribution
|
Q37127158
|
P2860
|
Q69685712
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Repair capacity and kinetics of human skin during fractionated radiotherapy: erythema, desquamation, and telangiectasia after 3 and 5 year's follow-up
|
Q37127158
|
P2860
|
Q70572133
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Recovery from radiation damage in mouse lung: interpretation in terms of two rates of repair
|
Q37127158
|
P2860
|
Q72899748
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Repair rate in mouse lung after clinically relevant radiation doses per fraction
|
Q37127158
|
P2860
|
Q71251979
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
The influence of the number of fractions and bi-exponential repair kinetics on biological equivalence in pulsed brachytherapy
|
Q37127158
|
P2860
|
Q73292311
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Biological effect of pulsed dose rate brachytherapy with stepping sources if short half-times of repair are present in tissues
|
Q37127158
|
P2860
|
Q73801853
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
cites work
|
Pulsed brachytherapy as a substitute for continuous low dose rate: comment on Chen, Huang, Hall, and Brenner's paper
|
Q37127158
|
P407
|
Q1860
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
language of work or name
|
English
|
Q37127158
|
P921
|
Q896687
|
Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma
|
main subject
|
brachytherapy
|
Q37127191
|
P31
|
Q13442814
|
Randomized controlled trials: methodological concepts and critique
|
instance of
|
scholarly article
|
Q37127191
|
P31
|
Q7318358
|
Randomized controlled trials: methodological concepts and critique
|
instance of
|
review article
|
Q37127191
|
P1433
|
Q7104844
|
Randomized controlled trials: methodological concepts and critique
|
published in
|
Orthopaedic Nursing (journal)
|
Q37127191
|
P407
|
Q1860
|
Randomized controlled trials: methodological concepts and critique
|
language of work or name
|
English
|
Q37127191
|
P921
|
Q1436668
|
Randomized controlled trials: methodological concepts and critique
|
main subject
|
randomized controlled trial
|
Q37127212
|
P31
|
Q13442814
|
Determinants of disability in chronic musculoskeletal health conditions: a literature review
|
instance of
|
scholarly article
|
Q37127212
|
P1433
|
Q5412742
|
Determinants of disability in chronic musculoskeletal health conditions: a literature review
|
published in
|
European Journal of Physical and Rehabilitation Medicine
|
Q37127212
|
P921
|
Q12131
|
Determinants of disability in chronic musculoskeletal health conditions: a literature review
|
main subject
|
disability
|
Q37127214
|
P31
|
Q13442814
|
Electrostatics in the ribosomal tunnel modulate chain elongation rates
|
instance of
|
scholarly article
|
Q37127214
|
P1433
|
Q925779
|
Electrostatics in the ribosomal tunnel modulate chain elongation rates
|
published in
|
Journal of Molecular Biology
|
Q37127214
|
P2860
|
Q36726739
|
Electrostatics in the ribosomal tunnel modulate chain elongation rates
|
cites work
|
SRP keeps polypeptides translocation-competent by slowing translation to match limiting ER-targeting sites
|
Q37127214
|
P2860
|
Q36915705
|
Electrostatics in the ribosomal tunnel modulate chain elongation rates
|
cites work
|
Following translation by single ribosomes one codon at a time.
|
Q37127214
|
P2860
|
Q29619435
|
Electrostatics in the ribosomal tunnel modulate chain elongation rates
|
cites work
|
A "silent" polymorphism in the MDR1 gene changes substrate specificity
|
Q37127214
|
P2860
|
Q33911236
|
Electrostatics in the ribosomal tunnel modulate chain elongation rates
|
cites work
|
Nascent peptide-mediated translation elongation arrest coupled with mRNA degradation in the CGS1 gene of Arabidopsis
|
Q37127214
|
P2860
|
Q37356413
|
Electrostatics in the ribosomal tunnel modulate chain elongation rates
|
cites work
|
A nascent polypeptide domain that can regulate translation elongation
|
Q37127214
|
P2860
|
Q34182941
|
Electrostatics in the ribosomal tunnel modulate chain elongation rates
|
cites work
|
Functional analysis of an archaebacterial voltage-dependent K+ channel
|